overactive bladder
Conditions
Interventions
Take Vibegron (50mg / day) for 4week.
Sponsors
GIFU UNIVERSITY
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Male patient diagnosed with BPH. 2.Patients receiving silodosin for 4 weeks at the time of registration. 3.Patients whose OABSS total score exceeds 3 points and urinary urgency exceeds 1 / week (OABSS urgency score of 2 points or more). 4.Patients who are over 50 years old and under 90 years old when obtaining consent. 5.Patients who have obtained written consent for participation in this study.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of hypersensitivity to silodosin or Vibegron. 2.Patients who have started taking anticholinergic drugs, cholinergic drugs, beta3 agonists, beta antagonists, alpha-receptor blockers and other frequent urinary/urinary incontinence drugs within 8 weeks (excluding silodosin). In addition, a 5alpha-reductase inhibitor or an antiandrogen is administered 6months or more in advance and can be incorporated if the patient's condition is stable. 3.Patients with urinary retention or severe urination difficulty or patients with a history of urination. 4.Patients with neoplasms in the lower urinary tract such as bladder cancer and prostate cancer, neurogenic bladder, urethral stricture, chronic bacterial prostatitis, active urinary tract infection, urinary calculus, interstitial cystitis. 5.Patients who have more than 100mL of residual urine at the time of consent and registration. 6.Patients who are judged to be inappropriate as the subject of researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in overactive bladder symptoms questionnaire (OABSS) total score. | — |
Countries
Japan
Contacts
Public ContactHIROKI ITO
GIFU UNIVERSITY HOSPITAL urology
Outcome results
None listed